This is a Phase Ib multicenter, open-label study of C-CAR066, an autologous anti-CD20 Chimeric Antigen Receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).~This trial will employ the Bayesian optimal interval (BOIN) design, with a dosing finding Run-In, to find the MTD and/or determine the recommended Phase 2 dose (RP2D).
The goal of this multicenter study is to test C-CAR066 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are:~is C-CAR066 safe and do patients tolerate it well?~what is the best dose of C-CAR066?~will C-CAR066 help patients achieve a response and for how long?